Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
55.82
+0.91 (1.66%)
At close: Mar 28, 2025, 4:00 PM
57.69
+1.87 (3.35%)
After-hours: Mar 28, 2025, 7:46 PM EDT
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
$553,216
Profits / Employee
$69,455
Market Cap
137.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
Dec 31, 2017 | 106,566 | -293 | -0.27% |
Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
Dec 31, 2013 | 112,128 | 154 | 0.14% |
Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
Dec 31, 2007 | 99,495 | -794 | -0.79% |
Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
Dec 31, 2005 | 97,181 | 742 | 0.77% |
Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
Dec 31, 2003 | 33,086 | 650 | 2.00% |
Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
SNY News
- 11 hours ago - Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - GlobeNewsWire
- 13 hours ago - US FDA approves Sanofi's bleeding disorder therapy - Reuters
- 18 hours ago - AbbVie Vs. Sanofi: Which Is The Better Investment Right Now - Seeking Alpha
- 1 day ago - Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD - GlobeNewsWire
- 3 days ago - Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA - GlobeNewsWire
- 4 days ago - Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis - GlobeNewsWire
- 5 days ago - Press Release: Availability of the Q1 2025 Aide mémoire - GlobeNewsWire
- 9 days ago - Sanofi to acquire Dren Bio's immunology unit - Reuters